CNS Drugs

, Volume 26, Issue 12, pp 1073–1083 | Cite as

Gabapentin Enacarbil

In Patients with Restless Legs Syndrome
Adis Drug Profile

Abstract

Oral gabapentin enacarbil is approved in adult patients for the treatment of moderate to severe primary restless legs syndrome (RLS) [featured indication] and the management of postherpetic neuralgia. In the 12-week Patient Improvements in Vital Outcomes following Treatment (PIVOT) RLS I and II trials in adult patients with moderate to severe primary RLS (n > 500 total evaluable), once-daily gabapentin enacarbil 600 or 1,200 mg significantly improved mean International Restless Legs Scale (IRLS) total scores compared with placebo, with significantly higher investigator-rated Clinical Global Impression-Improvement (CGI-I) responder rates in gabapentin enacarbil groups than in placebo groups. Improvements in other sleep outcomes (assessed using various scales) also generally favoured gabapentin enacarbil treatment. These data are supported by results from a polysomnography, crossover (two 4-week treatment periods) trial (n > 100 evaluable). Improvements in RLS symptoms with gabapentin enacarbil were maintained in a 52-week extension study of clinical trials, including PIVOT RLS I and II. The longer-term efficacy of gabapentin enacarbil in patients with moderate to severe RLS was also demonstrated in the 36-week PIVOT RLS Maintenance study and a 52-week noncomparative study conducted in Japan. Gabapentin enacarbil was generally well tolerated in adult patients with RLS participating in short- and longer-term clinical trials. The most common treatment-emergent adverse events were somnolence/sedation and dizziness. Most adverse events were of mild to moderate severity, with relatively few patients discontinuing treatment because of an adverse event.

References

  1. 1.
    Leschziner G, Gringras P. Restless legs syndrome. BMJ. 2012;344:e3056.PubMedCrossRefGoogle Scholar
  2. 2.
    Yaltho TC, Ondo WG. The use of gabapentin enacarbil in the treatment of restless legs syndrome. Ther Adv Neurol Disord. 2010;3(5):269–75.PubMedCrossRefGoogle Scholar
  3. 3.
    Satija P, Ondo WG. Restless legs syndrome: pathophysiology, diagnosis and treatment. CNS Drugs. 2008;22(6):497–518.PubMedCrossRefGoogle Scholar
  4. 4.
    Sivam S, Yee BJ. Role of gabapentin enacarbil XR in restless legs syndrome. Ther Clin Risk Manag. 2012;8:201–8.PubMedCrossRefGoogle Scholar
  5. 5.
    National Institute of Neurological Disorders and Stroke. Restless legs syndrome fact sheet [online]. Available from URL: http://www.ninds.nih.gov/disorders/restless_legs/detail_restless_legs.htm. Accessed 15 Oct 2012.
  6. 6.
    Cundy KC, Branch R, Chernov-Rogan T, et al. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: I. Design, synthesis, enzymatic conversion and transport by intestinal solute transporters. J Pharmacol Exp Ther. 2004;311(1):315–23.PubMedCrossRefGoogle Scholar
  7. 7.
    GlaxoSmithKline, XenoPort Inc. Horizant (gabapentin enacarbil) extended-release tablets for oral use: US prescribing information [online]. Available from URL: http://us.gsk.com/products/assets/us_horizant.pdf. Accessed 23 Aug 2012.
  8. 8.
    Lal R, Sukbuntherng J, Luo W, et al. Population pharmacokinetics and pharmacodynamics of gabapentin after administration of gabapentin enacarbil. J Clin Pharmacol. 2012. doi:10.1177/0091270012439209.
  9. 9.
    Chen D, Lal R, Zomorodi K, et al. Evaluation of gabapentin enacarbil on cardiac repolarization: a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults. Clin Ther. 2012;34(351–62):e3.PubMedGoogle Scholar
  10. 10.
    Lal R, Sukbuntherng J, Luo W, et al. Pharmacokinetics and tolerability of single escalating doses of gabapentin enacarbil: a randomized-sequence, double-blind, placebo-controlled crossover study in healthy volunteers. Clin Ther. 2009;31(8):1776–86.PubMedCrossRefGoogle Scholar
  11. 11.
    Cundy KC, Annamalai T, Bu L, et al. XP13512 [(±)-1-([(alpha-isobutanoyloxyethoxy)carbonyl] aminomethyl)-1-cyclohexane acetic acid], a novel gabapentin prodrug: II. Improved oral bioavailability, dose proportionality, and colonic absorption compared with gabapentin in rats and monkeys. J Pharmacol Exp Ther. 2004;311(1):324–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Lal R, Ellenbogen A, Chen D, et al. A randomized, double-blind, placebo-controlled, dose-response study to assess the pharmacokinetics, efficacy, and safety of gabapentin enacarbil in subjects with restless legs syndrome. Clin Neuropharmacol. 2012;35(4):165–73.PubMedCrossRefGoogle Scholar
  13. 13.
    Cundy KC, Sastry S, Luo WD, et al. Clinical pharmacokinetics of XP13512, a novel transported prodrug of gabapentin. J Clin Pharmacol. 2008;48(12):1378–88.PubMedCrossRefGoogle Scholar
  14. 14.
    Lal R, Sukbuntherng J, Luo W, et al. The effect of food with varying fat content on the clinical pharmacokinetics of gabapentin after oral administration of gabapentin enacarbil. Int J Clin Pharmacol Ther. 2010;48(2):120–8.PubMedGoogle Scholar
  15. 15.
    Lal R, Sukbuntherng J, Ho J, et al. A phase I, single-dose study of the disposition of 14C-radiolabeled gabapentin enacarbil in healthy male volunteers. Int J Clin Pharmacol Ther. 2011;49(2):109–15.PubMedGoogle Scholar
  16. 16.
    Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetics of gabapentin after administration of gabapentin enacarbil extended-release tablets in patients with varying degrees of renal function using data from an open-label, single-dose pharmacokinetic study. Clin Ther. 2012;34(1):201–13.PubMedCrossRefGoogle Scholar
  17. 17.
    Lal R, Sukbuntherng J, Luo W, et al. Clinical pharmacokinetic drug interaction studies of gabapentin enacarbil, a novel transported prodrug of gabapentin, with naproxen and cimetidine. Br J Clin Pharmacol. 2010;69(5):498–507.PubMedCrossRefGoogle Scholar
  18. 18.
    Kushida CA, Becker PM, Ellenbogen AL, et al. Randomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLS. Neurology. 2009;72(5):439–46.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee DO, Ziman RB, Perkins AT, et al. A randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndrome. J Clin Sleep Med. 2011;7(3):282–92.PubMedGoogle Scholar
  20. 20.
    Winkelman JW, Bogan RK, Schmidt MH, et al. Randomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndrome. Mov Disord. 2011;26(11):2065–72.PubMedCrossRefGoogle Scholar
  21. 21.
    Bogan R, Ellenbogen AL, Becker PM, et al. Gabapentin enacarbil improves RLS symptoms and subjective measures of sleep in subjects with primary restless legs syndrome with and without severe sleep disturbance: secondary analyses from two studies [abstract no. P02.283]. In: 62nd Annual Meeting of the American Academy of Neurology; 2010 April 10–17; Toronto.Google Scholar
  22. 22.
    VanMeter SA, Kavanagh ST, Warren S, et al. Dose response of gabapentin enacarbil versus placebo in subjects with moderate-to-severe primary restless legs syndrome: an integrated analysis of three 12-week studies. CNS Drugs. 2012;26(9):773–80.PubMedCrossRefGoogle Scholar
  23. 23.
    Canafax DM, Bhanegaonkar A, Bharmal M, et al. Validation of the post sleep questionnaire for assessing subjects with restless legs syndrome: results from two double-blind, multicenter, placebo-controlled clinical trials. BMC Neurol. 2011;11:48.PubMedCrossRefGoogle Scholar
  24. 24.
    Lee D, Ziman R, Perkins A, et al. Gabapentin enacarbil improves pain associated with restless legs syndrome (RLS) [abstract no. 311]. J Pain. 2010;11(4 Suppl. 1):S53.Google Scholar
  25. 25.
    Bogan RK, Bornemann MAC, Kushida CA, et al. Long-term maintenance treatment of restless legs syndrome with gabapentin enacarbil: a randomized controlled study. [Erratum appears in Mayo Clin Proc. 2010, 85(7), pp. 693–4]. Mayo Clin Proc. 2010;85(6):512–21.PubMedCrossRefGoogle Scholar
  26. 26.
    Ellenbogen AL, Thein SG, Winslow DH, et al. A 52-week study of gabapentin enacarbil in restless legs syndrome. Clin Neuropharmacol. 2011;34(1):8–16.PubMedCrossRefGoogle Scholar
  27. 27.
    Inoue Y, Uchimura N, Kuroda K, et al. Long-term efficacy and safety of gabapentin enacarbil in Japanese restless legs syndrome patients. Prog Neuro Psychopharmacol Biol Psychiatry. 2012;36(2):251–7.CrossRefGoogle Scholar
  28. 28.
    Irizarry MC, Webb DJ, Boudiaf N, et al. Risk of cancer in patients exposed to gabapentin in two electronic medical record systems. Pharmacoepidem Drug Safety. 2012;21:214–25.CrossRefGoogle Scholar
  29. 29.
    Astellas Pharma Inc., XenoPort Inc. Astellas and XenoPort announce the launch of Regnite® tablets for restless legs syndrome in Japan [online]. Available from URL: http://www.astellas.co/en/corporate/news/pdf/120709.eg.pdf Accessed 23 Aug 2012.
  30. 30.
    Aurora RN, Kristo DA, Bista SR, et al. The treatment of restless legs syndrome and periodic limb movement disorders in adults: an update for 2012. Practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice Guideline. Sleep. 2012;35(8):1039–62.PubMedGoogle Scholar
  31. 31.
    International Restless Legs Syndrome Study Group Task Force. Summary of recommendations for the long-term treatment of RLS/WED from an IRLSSG task force [online]. Available from URL: http://irlssg.org/wp-content/uploads/2012/07/Summary-of-RLS-treatment-recommendations-FINAL.pdf. Accessed 15 Oct 2012.
  32. 32.
    Vignatelli L, Billiard M, Clarenbach P, et al. EFNS guidelines on management of restless legs syndrome and periodic limb movement disorder in sleep. Eur J Neurol. 2006;13(10):1049–65.PubMedCrossRefGoogle Scholar

Copyright information

© Springer International Publishing Switzerland 2012

Authors and Affiliations

  1. 1.AdisAucklandNew Zealand

Personalised recommendations